We are currently experiencing technical issues due to the Microsoft outage. This will affect delivery of multi-factor authentication emails, invoice emails and service emails. We apologise for the disruption.

Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesGuardant Health Inc

Guardant Health Inc

Healthcare Diagnostics & Research
PortfolioPortfolio WatchlistWatchlist
Company price
155.845 USD 1.06 ( 0.69%)
Last update at 2026-11-12T15:40:00Z
VOLUME
868588
Market Cap
11852.56M

Momentum Score

…

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally. The company offers Guardant360 CDx test, a liquid biopsy test for tumor mutation profiling; Guardant360 Liquid test, which measures 740+ genes and supports all guideline-recommended biomarkers; Guardant Reveal test, a blood test that utilizes circulating tumor DNA to detect cancer at the molecular level; and Guardant360 Tissue test, a molecular profiling test for tumor tissue that provides genomic, transcriptomic, and epigenomic insights. It also provides Shield blood test for colorectal cancer screening in adults. In addition, the company offers GuardantINFINITY test that provides insights into the complexities of tumor molecular profiles and immune response to advance cancer research and therapy development; GuardantOMNI test covers 500 genes, including genes associated with homologous recombination repair deficiency and biomarkers for immuno-oncology applications; GuardantINFORM, which provides longitudinal biological insight into tumor evolution alongside longitudinal clinical outcomes; and GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies. Further, it provides Smart Platform, which delivers multiomic insights leveraging genomic, epigenomic, and RNA-based data that are scalable from research to the clinic. Additionally, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kit fulfillment and delivery of Shield screening tests. Guardant Health, Inc. was incorporated in 2011 and is headquartered in Palo Alto, California.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
153.05
Low
158.34
High
52 Week Price Range
36.36
Low
120.74
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Guardant Health offers blood-based genomic tests that analyze circulating tumor DNA to inform cancer treatment, monitoring and clinical trials; Guardant360 and related assays are used as companion diagnostics. Long-term growth could be supported by broader adoption of liquid biopsy, expansion into early-stage detection and surveillance, and pharma partnerships, which may make it attractive to investors seeking exposure to a scalable diagnostics platform.
Principal risks are reimbursement and regulatory uncertainty, strong competition from established diagnostics firms, and ongoing operating losses that create funding and execution risk.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
154.78
Dividend Yield
-
Revenue TTM
982.02M
Revenue Per Share
7.83
Gross Profit TTM
633.01M
Debt / Equity
-16.94
ROE
-4584.47%
Net Debt
1304.26M
ROCE
-24.18%
Diluted EPS TTM
-3.32

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -417.54M -435.09M -478.76M -653.45M -384.47M
Minority interest - - 0.00M 0.00M -20.90M
Net income -416.28M -436.37M -479.45M -654.59M -384.77M
Selling general administrative 211.41M 180.12M 155.80M 163.96M 206.64M
Selling and marketing expenses 494.66M 364.94M 295.23M 299.83M 191.88M
Gross profit 633.01M 449.22M 336.90M 293.21M 250.74M
Reconciled depreciation 39.74M 42.39M 42.88M 35.96M 22.27M
Ebit -413.64M -432.51M -476.19M -544.38M -411.00M
Ebitda -373.91M -390.12M -433.31M -650.87M -381.89M
Depreciation and amortization 39.74M 42.39M 42.88M -106.49M 29.11M
Non operating income net other - - - -106.49M 29.11M
Operating income -436.30M -443.59M -564.73M -544.38M -411.00M
Other operating expenses 1419.27M 1182.61M 1128.67M 993.92M 784.65M
Interest expense 3.90M 2.58M 2.58M 2.58M 2.58M
Tax provision -1.26M 1.28M 0.69M 1.14M 0.30M
Interest income 34.09M 53.69M 35.37M 6.07M 3.93M
Net interest income 30.20M 51.11M 32.79M 3.49M 1.35M
Income tax expense -1.26M 1.28M 0.69M 1.14M 0.30M
Total revenue 982.02M 739.02M 563.95M 449.54M 373.65M
Total operating expenses 1070.26M 892.81M 901.62M 837.59M 661.74M
Cost of revenue 349.01M 289.80M 227.05M 156.32M 122.91M
Total other income expense net 18.76M 8.51M 85.96M -109.07M 26.53M
Net income from continuing ops -416.28M -436.37M -479.45M -654.59M -384.77M
Net income applicable to common shares - - - -654.59M -405.67M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 2013.66M 1485.61M 1786.42M 1609.98M 2204.50M
Intangible assets 25.92M 6.76M 8.98M 11.73M 14.21M
Other current assets 40.72M 33.80M 27.74M 31.51M 53.05M
Total liab 2112.97M 1625.26M 1627.74M 1549.81M 1559.49M
Total stockholder equity -99.31M -139.65M 158.68M 60.18M 645.00M
Other current liab 197.53M 122.35M 108.26M -21.88M 152.93M
Common stock 0.00M 0.00M 0.00M 0.00M 0.00M
Capital stock 0.00M 0.00M 0.00M 0.00M 0.00M
Retained earnings -2994.51M -2578.24M -2141.86M -1662.41M -1007.83M
Other liab - - - 9.18M 3.93M
Good will 77.26M 3.29M 3.29M 3.29M 3.29M
Other assets - - - 36.45M 60.94M
Cash 378.20M 525.54M 1133.54M 141.65M 492.20M
Total current liabilities 302.73M 225.58M 205.92M 193.22M 194.69M
Current deferred revenue 50.75M 35.47M 17.96M 17.40M 11.33M
Net debt 1304.26M 810.51M 220.23M 1227.64M 868.67M
Short term debt - 29.21M 27.95M 21.88M 12.86M
Short long term debt total 1682.46M 1336.05M 1353.76M 1369.28M 1360.87M
Other stockholder equity 2900.06M 2443.79M 2304.22M 1742.11M 1657.59M
Property plant equipment - - - 167.92M 313.90M
Total current assets 1466.05M 1055.11M 1347.11M 1191.59M 1114.13M
Long term investments - - - 0.00M 698.03M
Net tangible assets - - - 45.16M 627.51M
Short term investments 823.39M 314.44M 35.10M 869.58M 440.55M
Net receivables 137.85M 110.25M 88.78M 97.26M 97.65M
Long term debt 1504.00M 1142.55M 1139.97M 1137.39M 1134.82M
Inventory 85.88M 71.08M 61.95M 51.60M 30.67M
Accounts payable 54.44M 38.55M 51.74M 175.82M 17.58M
Accumulated other comprehensive income -4.85M -5.20M -3.67M -19.52M -4.76M
Common stock total equity - - - 0.00M 0.00M
Retained earnings total equity - - - -1662.41M -1007.83M
Non currrent assets other 139.67M 141.37M 124.18M 61.45M 60.94M
Non current assets total 547.61M 430.50M 439.31M 418.39M 1090.37M
Capital lease obligations 206.14M 193.50M 213.80M 231.89M 226.05M
Long term debt total - - - 1137.39M 1134.82M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments -519.91M -261.31M 247.42M 149.82M 51.30M
Change to liabilities - - - 9.87M 37.57M
Total cashflows from investing activities -627.20M -261.31M 840.25M 149.82M -63.16M
Net borrowings 402.50M 0.00M 0.00M -0.07M -0.78M
Total cash from financing activities 671.13M -1.00M 477.38M -189.09M -66.82M
Change to operating activities - - - 11.91M 0.43M
Net income -416.28M -436.37M -479.45M -654.59M -384.77M
Change in cash -140.34M -503.93M 991.74M -842.63M -340.69M
Begin period cash flow 629.75M 1133.69M 141.95M 492.29M 832.98M
End period cash flow 489.42M 629.75M 1133.69M -350.34M 492.29M
Total cash from operating activities -184.76M -239.86M -324.98M -309.46M -209.02M
Issuance of capital stock 345.00M 0.00M 493.12M - 0.00M
Depreciation 39.74M 42.39M 42.88M 35.96M 22.27M
Other cashflows from investing activities - - 1.53M -23.97M -39.42M
Change to inventory -14.79M -9.13M -10.35M -20.93M -7.96M
Change to account receivables -28.18M -21.39M 8.38M 0.38M -44.35M
Sale purchase of stock 13.59M 11.72M 10.15M 9.32M 9.75M
Other cashflows from financing activities 569.68M -15.83M -15.74M -200.96M -76.43M
Change to netincome - - - 104.27M 153.88M
Capital expenditures 48.31M 35.09M 20.49M 77.46M 75.03M
Change receivables - - - 0.38M -44.35M
Cash flows other operating - - - 208.41M -1.07M
Cash and cash equivalents changes - - - -348.74M -339.00M
Change in working capital 9.78M -60.86M 53.84M 61.56M -40.47M
Stock based compensation 166.22M 140.41M 90.76M 94.69M 151.45M
Other non cash items 15.78M 74.58M -33.01M 152.91M 29.61M
Free cash flow -233.07M -274.94M -345.46M -386.92M -284.05M

Peer Comparison*

Sector: Healthcare Industry: Diagnostics & Research

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
GH
Guardant Health Inc		 1.06
0.69%		 155.84 - - 12.07 55.67 12.68 -5.40
TMO
Thermo Fisher Scientific Inc		 -15.12
2.11%		 702.59 34.71 23.87 4.62 4.43 5.29 20.89
DHR
Danaher Corporation		 -1.34
0.57%		 233.97 29.09 28.01 5.67 3.20 6.00 19.09
WUXIF
WuXi AppTec Co. Ltd		 -
-%		 24.91 22.29 17.95 1.53 5.98 8.39 14.30
WUXAY
WuXi AppTec Co. Ltd		 -0.17
0.68%		 24.93 23.28 18.73 1.51 6.24 8.39 14.30

Profile*

Guardant Health Inc

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally. The company offers Guardant360 CDx test, a liquid biopsy test for tumor mutation profiling; Guardant360 Liquid test, which measures 740+ genes and supports all guideline-recommended biomarkers; Guardant Reveal test, a blood test that utilizes circulating tumor DNA to detect cancer at the molecular level; and Guardant360 Tissue test, a molecular profiling test for tumor tissue that provides genomic, transcriptomic, and epigenomic insights. It also provides Shield blood test for colorectal cancer screening in adults. In addition, the company offers GuardantINFINITY test that provides insights into the complexities of tumor molecular profiles and immune response to advance cancer research and therapy development; GuardantOMNI test covers 500 genes, including genes associated with homologous recombination repair deficiency and biomarkers for immuno-oncology applications; GuardantINFORM, which provides longitudinal biological insight into tumor evolution alongside longitudinal clinical outcomes; and GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies. Further, it provides Smart Platform, which delivers multiomic insights leveraging genomic, epigenomic, and RNA-based data that are scalable from research to the clinic. Additionally, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kit fulfillment and delivery of Shield screening tests. Guardant Health, Inc. was incorporated in 2011 and is headquartered in Palo Alto, California.

3100 Hanover Street, Palo Alto, CA, United States, 94304

855 698 8887

https://guardanthealth.com

2490

Name Title Year Born
Dr. Helmy Eltoukhy Ph.D. Co-Founder, Co-CEO & Chairman 1979
Dr. AmirAli Talasaz Ph.D. Co-CEO & Director 1980
Mr. Michael Bell Chief Financial Officer 1969
Mr. John G. Saia Chief Legal Officer 1973
Dr. Craig Eagle M.D. Chief Medical Officer 1967
Mr. Christopher Freeman Chief Commercial Officer of Oncology Bus. 1974
Mr. Andy Ament Sr. VP of Operations NA
Darya Chudova Sr. VP of Technology NA
Mr. Kumud Kalia Chief Information Officer NA
Ms. Jennifer Higgins VP of Public Affairs NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

CJT
CAD 111.15
+12.71%
CLS
CAD 374.20
+8.33%
GRZ
CAD 4.90
+7.46%
CTC-A
CAD 218.05
+6.38%
FEC
CAD 7.42
+5.85%
TF
CAD 4.13
-19.65%
TLO
CAD 5.98
-15.06%
FSZ
CAD 2.45
-14.04%
XNDU
CAD 3.60
-8.86%
ITR
CAD 2.75
-8.50%

Equity Sectors*

  • Basic Materials

    -2.63%

  • Communication Services

    -0.79%

  • Consumer Cyclical

    +0.08%

  • Consumer Defensive

    -0.12%

  • Energy

    +0.52%

  • Financial Services

    -1.15%

  • Healthcare

    -1.74%

  • Industrials

    -0.64%

  • Real Estate

    -0.12%

  • Technology

    -0.51%

  • Utilities

    -0.02%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…